- Home
- RDGT vs RNAZ Comparison
RDGT vs RNAZ Comparison
Compare RDGT & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDGT
- RNAZ
- Stock Information
- Founded
- RDGT N/A
- RNAZ 2016
- Country
- RDGT China
- RNAZ United States
- Employees
- RDGT N/A
- RNAZ N/A
- Industry
- RDGT
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- RDGT
- RNAZ Health Care
- Exchange
- RDGT NYSE
- RNAZ Nasdaq
- Market Cap
- RDGT 5.7M
- RNAZ 6.1M
- IPO Year
- RDGT N/A
- RNAZ 2021
- Fundamental
- Price
- RDGT $1.10
- RNAZ $7.97
- Analyst Decision
- RDGT
- RNAZ Strong Buy
- Analyst Count
- RDGT 0
- RNAZ 1
- Target Price
- RDGT N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- RDGT 7.4K
- RNAZ 32.8K
- Earning Date
- RDGT 07-29-2025
- RNAZ 08-13-2025
- Dividend Yield
- RDGT N/A
- RNAZ N/A
- EPS Growth
- RDGT N/A
- RNAZ N/A
- EPS
- RDGT N/A
- RNAZ N/A
- Revenue
- RDGT $147,126,392.00
- RNAZ N/A
- Revenue This Year
- RDGT N/A
- RNAZ N/A
- Revenue Next Year
- RDGT N/A
- RNAZ N/A
- P/E Ratio
- RDGT N/A
- RNAZ N/A
- Revenue Growth
- RDGT N/A
- RNAZ N/A
- 52 Week Low
- RDGT $0.72
- RNAZ $6.15
- 52 Week High
- RDGT $4.50
- RNAZ $970.20
- Technical
- Relative Strength Index (RSI)
- RDGT N/A
- RNAZ 47.04
- Support Level
- RDGT N/A
- RNAZ $7.32
- Resistance Level
- RDGT N/A
- RNAZ $8.48
- Average True Range (ATR)
- RDGT 0.00
- RNAZ 0.58
- MACD
- RDGT 0.00
- RNAZ 0.41
- Stochastic Oscillator
- RDGT 0.00
- RNAZ 70.77
About RDGT RIDGETECH INC
Ridgetech Inc formerly China Jo-Jo Drugstores Inc is a retailer and distributor of pharmaceutical products. The company's operating segments include Retail drugstores, Online Pharmacy, and Drug wholesale. Retail drugstores segment sells prescription and over-the-counter medicines, TCM, dietary supplements, medical devices, and sundry items to retail customers. The online pharmacy segment sells drugs through third-party platforms such as Alibaba's Tmall, JD.com, and Amazon.com. It generates maximum revenue from the Retail drugstores segment.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.